Article (Scientific journals)
Etude clinique du mois. L'etude DREAM: prevention du diabete de type 2 par le ramipiril et/ou la rosiglitazone chez les personnes dysglycemiques sans maladie cardio-vasculaire.
Scheen, André
2006In Revue Médicale de Liège, 61 (10), p. 728-32
Peer reviewed
 

Files


Full Text
200610_12.pdf
Publisher postprint (452.39 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adult; Angiotensin-Converting Enzyme Inhibitors/therapeutic use; Diabetes Mellitus, Type 2/etiology/prevention & control; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperglycemia/complications; Hypoglycemic Agents/therapeutic use; Male; Middle Aged; Ramipril/therapeutic use; Thiazolidinediones/therapeutic use
Abstract :
[en] DREAM ("Diabetes Reduction Assessment with ramipril and rosiglitazone Medication") is a double-blind randomised placebo-controlled clinical trial with a 2-by-2 factorial design aiming to study the effects of an ACE inhibitor (ramipril 15 mg/day) and/or a thiazolidinedione (rosiglitazone 8 mg/day) on the development of diabetes or death (primary outcome) and on the regression to normoglycaemia (secondary outcome) in 5269 adults aged 30 years or more with impaired fasting glucose and/or impaired glucose tolerance, and no previous cardiovascular disease. There was no statistical evidence of an interaction between the ramipril and the rosiglitazone arms. After a mean follow up of 3 years, the use of ramipril does not significantly reduce the incidence of diabetes or death but does significantly increase regression to normoglycaemia. In contrast, the treatment with rosiglitazone reduces by almost 60% the incidence of type 2 diabetes and increases the likelihood (+70%) of regression to normoglycaemia. Whether it is a true prevention effect or simply a treatment effect remains to be determined when participants will be retested after a washout period. Cardiovascular event rates were rather low and much the same in all treatment groups, except a higher rate of heart failure in the rosiglitazone group. These results suggest that the routine inhibition of the renin-angiotensin system for the express purpose of preventing diabetes is not indicated in individuals not at high risk for cardiovascular disease and appear to confirm the promises of the glitazone use in the very early stage of the natural history of type 2 diabetes.
Disciplines :
Cardiovascular & respiratory systems
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
French
Title :
Etude clinique du mois. L'etude DREAM: prevention du diabete de type 2 par le ramipiril et/ou la rosiglitazone chez les personnes dysglycemiques sans maladie cardio-vasculaire.
Alternative titles :
[en] DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease
Publication date :
2006
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
61
Issue :
10
Pages :
728-32
Peer reviewed :
Peer reviewed
Additional URL :
Available on ORBi :
since 02 March 2009

Statistics


Number of views
266 (2 by ULiège)
Number of downloads
214 (3 by ULiège)

Scopus citations®
 
15
Scopus citations®
without self-citations
13

Bibliography


Similar publications



Contact ORBi